Eukarÿs SAS

www.eukarys.com

Eukarÿs has developed the first ever artificial expression system able to synthesize in vivo autonomously messenger RNA (mRNA) and consequently the protein of interest in mammalian and other eukaryotic cells. Using the C3P3 system, Eukarÿs develop the unique synthetic gene therapy approach, which is a non-viral, safe, non-integrative, efficient, cost-effective, well-tolerated approach to treat human monogenic and multifactorial disorders. The same C3P3 system is also used for synthetic gene vaccination. For further information, see www.eukarys.com.

Read more

Reach decision makers at Eukarÿs SAS

Lusha Magic

Free credit every month!

Eukarÿs has developed the first ever artificial expression system able to synthesize in vivo autonomously messenger RNA (mRNA) and consequently the protein of interest in mammalian and other eukaryotic cells. Using the C3P3 system, Eukarÿs develop the unique synthetic gene therapy approach, which is a non-viral, safe, non-integrative, efficient, cost-effective, well-tolerated approach to treat human monogenic and multifactorial disorders. The same C3P3 system is also used for synthetic gene vaccination. For further information, see www.eukarys.com.

Read more
icon

Country

icon

City (Headquarters)

Évry

icon

Employees

1-10

icon

Founded

2010

icon

Social

  • icon

Employees statistics

View all employees

Potential Decision Makers

  • President and Chief Scientific Officer

    Email ****** @****.com
    Phone (***) ****-****
  • Special Advisor

    Email ****** @****.com
    Phone (***) ****-****

Reach decision makers at Eukarÿs SAS

Free credits every month!

My account

Sign up now to uncover all the contact details